Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study.
Youssra AllachMylene Barry-Loncq de JongPascal R D ClephasMarco W F van GentHans-Peter Brunner-La RoccaMariusz K SzymanskiVokko P van HalmM Louis HandokoWouter E M KokFolkert W AsselbergsRoland R J van KimmenadeOlivier C ManintveldNicolas M D A van MieghemSaskia L M A BeeresMichiel RienstraMarco C PostLoek van HeerebeekC Jan Willem BorleffsRaymond TukkieArend MosterdGerard C M LinssenRuud F SpeeMireille E EmansTom D J SmildeJan van RamshorstCharles J H J KirchhofMargriet W Feenema-AardemaCarlos A da FonsecaMieke van den HeuvelRonald HazelegerJ W Martijn van EckEric BoersmaIsabella KardysRudolf A de BoerJasper J BrugtsPublished in: European journal of heart failure (2024)
Since the prognostic value of single baseline measurements of biomarkers like N-terminal pro-B-type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively.